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Abstract
Background: Ischemia/reperfusion leads to inflammation and oxidative stress which damages membrane highly
polyunsaturated fatty acids (HPUFAs) and eventually induces neuronal death. This study evaluates the effect of the
administration of Pistacia lentiscus L. essential oil (E.O.), a mixture of terpenes and sesquiterpenes, on modifications
of fatty acid profile and endocannabinoid (eCB) congener concentrations induced by transient bilateral common
carotid artery occlusion (BCCAO) in the rat frontal cortex and plasma.
Methods: Adult Wistar rats underwent BCCAO for 20 min followed by 30 min reperfusion (BCCAO/R). 6 hours
before surgery, rats, randomly assigned to four groups, were gavaged either with E.O. (200 mg/0.45 ml of
sunflower oil as vehicle) or with the vehicle alone.
Results: BCCAO/R triggered in frontal cortex a decrease of docosahexaenoic acid (DHA), the membrane highly
polyunsaturated fatty acid most susceptible to oxidation. Pre-treatment with E.O. prevented this change and led
further to decreased levels of the enzyme cyclooxygenase-2 (COX-2), as assessed by Western Blot. In plasma, only
after BCCAO/R, E.O. administration increased both the ratio of DHA-to-its precursor, eicosapentaenoic acid (EPA),
and levels of palmytoylethanolamide (PEA) and oleoylethanolamide (OEA).
Conclusions: Acute treatment with E.O. before BCCAO/R elicits changes both in the frontal cortex, where the
BCCAO/R-induced decrease of DHA is apparently prevented and COX-2 expression decreases, and in plasma, where
PEA and OEA levels and DHA biosynthesis increase. It is suggested that the increase of PEA and OEA plasma levels
may induce DHA biosynthesis via peroxisome proliferator-activated receptor (PPAR) alpha activation, protecting
brain tissue from ischemia/reperfusion injury.
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Cerebral ischemia or stroke is often associated to unilat-
eral or bilateral occlusion of internal carotid artery or
common carotid artery [1-4]. Interruption of brain cir-
culation makes the cerebral tissue unable to sustain
basal metabolism and within a few seconds leads to
multiple interconnected pathophysiological events affect-
ing the structural and functional organization of brain
tissue [5,6].
Although reperfusion of neural ischemic tissue is
desirable, the post-ischemic reestablishment of blood
supply leads to a general impairment of translation cap-
ability, oxidative stress and free radical formation which
can eventually cause neuronal death [6-8]. Neuronal
membranes are particularly rich in highly polyunsatu-
rated fatty acids (HPUFAs) which serve as reservoirs of
biologically active lipids in physiological conditions,
whereas, in stressful circumstances, are target of free
radical-mediated lipid peroxidation whose products, in
turn, can injure the brain [9-11]. The brain has a unu-
sual ability to preserve the neuronal membrane concen-
tration of HPUFAs within a physiological range [12];
however, it is also particularly vulnerable to oxidative
stress due to the presence of uniquely high content of
HPUFAs, of an inadequate antioxidant defense system
and of high mitochondrial density [10,11]. Ischemia/
reperfusion may affect lipid turnover and cause the
release of free (unesterified) PUFAs from membrane
phospholipids [9]. The main products of lipid peroxida-
tion are fatty acid hydroperoxides which are quite
unstable and capable to propagate free radical reactions,
thus extending the damage [13].
Interestingly, recent studies point up the relationship
between brain metabolic stress and lipid peripheral dys-
regulation, showing that cleavage and immediate release
of membrane lipid precursors, such as eicosanoids,
could be useful indicators of central nervous system
(CNS) pathologies [14]. In addition, plasma lipid meta-
bolic alterations as a physiological response to brain
ischemic stimulus are triggered by ischemia/reperfusion
during carotid endoarterectomy in patients with carotid
stenosis [15] and endocannabinoid (eCB) plasma levels
have been shown to increase in patients with acute
ischemic stroke [16].
Epidemiological studies indicate that oxidative stress
and neuroinflammation are also factors associated with
the decline of function in the aging brain [17] and that
the regular consumption of natural products rich in
bioactive compounds is associated with vascular diseases,
stroke and dementia risk reduction [18-22]. Although the
mechanisms through which these compounds exert bene-
ficial effects wait to be clarified, their antioxidant, free
radical scavenging and anti-inflammatory properties are
supported by different experimental data [19,21-25]. The
Pistacia lentiscus L. plant is an aromatic bush indigenous
to Italy and other Mediterranean and Middle East coun-
tries. Its extracts have found extensive use in folk medi-
cine for their anti-hypertensive, anti-inflammatory and
antiseptic properties and for the treatment of gastric dis-
orders [26]. To our knowledge, the bioactive properties
of P. lentiscus L. extracts and/or individual components
have been reported only by in vitro studies where, with
different analytical methods, it has been shown that they
have a strong antioxidant activity [25,27-33]. Previous
analyses of P. lentiscus L. essential oil (E.O.) showed a
characteristic composition with relatively high concentra-
tion of terpenes and sesquiterpenes [27-33], for some of
which a potent anti-inflammatory activity has been
shown in different experimental rodent models
[21,22,34-36].
Because of the low extraction yield from P. lentiscus L.
plant, the E.O. under study has not generally received
much attention for its application in pharmaceutics and
has little commercial use. We sought to investigate the
potentially neuroprotective in vivo effects of dietary E.
O., obtained by Supercritical Fluid Extraction (SFE), in a
rat model of hypoperfusion achieved by transient bilat-
eral common carotid artery occlusion (BCCAO) fol-
lowed by reperfusion (BCCAO/R).
This study reports on modifications of fatty acid pro-
file and eCB congener concentrations induced by
BCCAO/R in the rat frontal cortex and plasma, and
shows that lipid metabolic changes are apparently pre-
vented by the administration of E.O.. Expression of the
enzyme cyclooxygenase-2 (COX-2) is also examined by
Western Blot on the same brains.
Methods
Extraction of P. lentiscus L. essential oil
Plant material
Leaves of P. lentiscus L. were collected during full blos-
som in northern Sardinia (Italy).
Reagents and standards
Highest purity solvents and reagents included Folin-
Ciocalteu reagent, methanol, hydrochloric acid (37%),
ferric chloride, sodium acetate trihydrate and sodium
acetate 6-hydrate (Merck, Darmstadt, Germany);
1,1-Diphenyl-2-picrylhydrazyl radical (DPPH, 98%) and
gallic acid (99%) (Sigma-Aldrich, Steinheim, Germany);
sodium carbonate anhydrous and 2,4,6-tris(2-pyridyl)-
S-triazine (TPTZ, P99%) (Fluka, Buchs, Germany); gla-
cial acetic acid (SDS, Penien, France); dichloromethane
(Lab-Scan, Dublin, Ireland). Chemical constituents of
the oil were identified by comparison with reference
compounds [Fluka, Acros Organics (Geel, Belgium);
Sigma-Aldrich].
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Supercritical CO2 (SFE) extractions were performed in a
laboratory apparatus, equipped with a 320 cm
3 extrac-
tion vessel and two separator vessels of 300 and 200
cm
3, respectively, connected in series [37]. Experiments
were carried out at P = 90 bars, T = 50°C and jCO2 =
0.6 kg/h. In the first separator the temperature was set
at -10°C and the pressure at the same value as the
extraction section. The second separator was set at 10°C
and 15 bars. Extraction was carried out in a semi batch
mode: batch charging of vegetable matter and continu-
ous flow solvent. About 180 g of material were charged
in each run.
Analysis
Analysis of essential oil was carried out by gas chroma-
tography (GC) and by gas chromatography-mass spec-
trometry (GC-MS). Analytical GC was carried out in an
Agilent 6890 gas chromatograph (Agilent Technologies,
Palo Alto, CA, USA) with HP GC ChemStation data
handling system, equipped with a single injector and
two flame ionization detectors (FID). A Graphpak divi-
der (Agilent Technologies) was used for simultaneous
sampling to two Supelco fused silica capillary columns
(Supelco Inc., Bellefonte, PA, USA) with different sta-
tionary phases: SPB-1 (polydimethylsiloxane 30 m ×
0.20 mm I.D., film thickness 0.20 μm) and SUPELCO-
WAX 10 (polyethylene glycol 30 m × 0.20 mm I.D., film
thickness 0.20 μm). Oven temperature was settled at 70°
C, raising at 3°C min
-1 to 220°C and then held 15 min
at 220°C; injector temperature: 250°C; carrier gas:
helium, adjusted to a linear velocity of 30 cm/s; splitting
ratio 1:40; detector temperature: 250°C.
GC-MS analyses were carried out in an Agilent 6890
gas chromatograph fitted with a HP1 fused silica col-
umn (polydimethylsiloxane 30 m × 0.25 mm I.D., film
thickness 0.25 μm), interfaced with an Hewlett Packard
mass selective detector 5973 (Agilent Technologies)
operated by Agilent Enhanced ChemStation software.
GC parameters as above; interface temperature: 250°C;
MS source temperature: 230°C; MS quadrupole tem-
perature: 150°C; ionization energy: 70 eV; ionization
current: 60 μA; scan range: 35-350 u; scans/sec: 4.51.
The identity of the components was assigned by com-
parison of mass spectra and retention indices for two
different chromatographic stationary phases calculated
by linear interpolation to the retention of a series of n-
alkanes. Experimental data were compared with corre-
sponding data of reference oils and commercial available
standards banked at a home-made library or from litera-
ture data [38,39]. Percentages of individual components
were calculated based on GC peak areas without FID
response factor correction.
Composition of the E.O. is reported in Table 1. The
total essential oil yield, after an extraction lasting 4
Table 1 Retention indices, IR and chromatographic area
percentages (%) of compounds found in E.O. extracted
by SFE at 90 bar, 50°C from Pistacia lentiscus L. leaves
n. Ik Compound %
1 922 tricyclene -
2 926 alpha-thujene 0.2
3 933 alpha-pinene 6.3
4 948 camphene 0.3
5 973 sabinene 5.8
6 977 beta-pinene 2.4
7 991 myrcene 3.9
8 1006 alpha-phellandrene 1.5
9 1016 alpha-terpinene 0.4
10 1024 para-cymene 0.8
11 1028 beta-phellandrene 3.7
12 1046 (E)-beta-ocimene -
13 1054 isopentil n-butanoate 0.2
14 1057 gamma-terpinene 0.7
15 n.i. 0.2
16 1088 terpinolene 0.2
17 1091 2-nonanone 0.2
18 n.i. 0.1
19 1101 linalool 0.2
20 1106 isopentyl isovalerate -
21 1177 terpin-4-ol 1.0
22 1190 alpha-terpineol 0.2
23 1250 n.i. 0.4
24 1253 n.i. 0.2
25 1285 bornyl acetate -
26 1294 2-undecanone 1.0
27 1302 n.i. -
28 1349 alpha-cubebene 0.2
29 1375 alpha-copaene 1.7
30 1389 beta-cubebene 1.1
31 1391 beta-elemene 1.3
32 1408 n.i. -
33 1418 beta-caryophyllene 6.6
34 1428 beta-gurjunene 0.2
35 1436 n.i. 0.7
36 1449 n.i. 0.3
37 1452 alpha-humulene 2.4
38 1459 allo-aromadendrene 0.9
39 1461 cis-muurola-4(14),5-diene -
40 1473 trans-cadina-1(6),4-diene -
41 1477 gamma-muurolene 2.9
42 1481 germacrene D 19.9
43 1485 beta-selinene -
44 1490 trans-muurola-4(15),5-diene 0.3
45 n.i. 1.9
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germacrene D (19.9%), beta-caryophyllene (BCP) (6.6%),
alpha-pinene (6.3%), myrcene (3.9%), beta-phellandrene
(3.7%) and alpha-humulene (2.4%).
Experimental procedure
Animals and keeping
Sixteen male Wistar rats (Harlan-Italy, Udine, Italy ),
weighing 210 ± 20 g (mean ± SD) were housed in an
environment of controlled temperature (21 ± 2°C), rela-
tive humidity (60 ± 5%) and under an artificial 12 h
light/dark cycle for 1 week before the experiment set
off. All stressful stimuli were avoided. Animal care and
handling throughout the experimental procedures were
in accordance with the European Communities Council
Directive of 24 November 1986 (86/609/EEC). The
experimental protocols were also approved by the Ani-
mal Ethics Committee of the University of Cagliari.
Standard laboratory food (Safe A04, France) and water
were freely available ad libitum.
Animals were starved for 12 hours before surgery and
6 hours prior to ischemia the E.O. was administered by
gavage. Due to the lack of data in the literature on the
use of E.O. in vivo, choice of the dose was based on the
concentration of some of the E.O. components, such as
BCP and alpha-humulene (Table 1), whose effectiveness
as single agents has been reported [34-36]. Since these
molecules have been shown to be active in contrasting
the symptoms of different models of inflammation in
the range of 5 to 100 mg/kg bodyweight [34-36], in the
present study each rat was administered 200 mg of E.O.
(containing about 60 mg/kg bodyweight of BCP and 22
mg/kg bodyweight of alpha-humulene) in 0.45 ml of
sunflower oil as vehicle. Rats were randomly assigned to
four groups, those submitted to BCCAO/R and the
sham-operated ones, treated with the vehicle alone or
with the vehicle containing the E.O..
Surgery
Surgery was performed in all cases between 15:00 and
17:30 p.m.. Rats were anesthetized with intraperitoneal
administration of chloral hydrate (80 mg/ml; 0.5 ml/
100 g bodyweight). After a midline cervical incision
and blunt dissection of muscles, the right and left com-
mon carotid arteries (CCA) were exposed while leaving
the vagus nerve intact. Transient bilateral ligation of
CCA, performed with a 0.28 mm nylon fishing line,
lasted 20 min. Blood flow was then restored through
the stenosed vessels for 30m i n .S h a mo p e r a t e dr a t s
underwent a surgical procedure similar to the other
groups but without the CCA occlusion. These animals
made up the control group used to determine the
effects of anaesthesia and surgical manipulation on the
results.
Sampling
At the end of the procedure, the animals, still anesthe-
tized, were sacrificed and different brain areas, i.e. olfac-
tory bulb, telencephalic cortex (subdivided in an
anterior third, including the frontal cortex, and the
remaining posterior two thirds, including parietal, tem-
poral, and occipital cortex), hippocampus, hypothala-
mus, striatum, brainstem and cerebellum were rapidly
dissected out and frozen at - 80°C until fatty acid or
western blot analysis. Blood was collected from the
trunk of killed rats into heparinised tubes and centri-
fuged at 1500 g for 10 min at - 8°C. The resulting
plasma was frozen at - 20°C until assayed for lipids.
Table 1 Retention indices, IR and chromatographic area
percentages (%) of compounds found in E.O. extracted
by SFE at 90 bar, 50?°?C from Pistacia lentiscus L. leaves
(Continued)
46 1495 alpha-selinene 1.7
47 1499 alpha-muurolene 1.6
48 1503 n.i. 0.9
49 1506 n.i. -
50 1509 beta-bisabolene 1.1
51 1513 gamma-cadinene 8.7
52 n.i. 0.2
53 1524 delta-cadinene 4.2
54 1531 trans-cadina-1(2)-4-diene 0.5
55 1536 alpha-cadinene -
56 1543 n.i. 0.4
57 1548 elemol 0.4
58 1555 n.i. 0.3
59 1557 elemicin 0.4
60 1564 (E)-nerolidol -
61 n.i. 0.7
62 1575 spatutenol 1.8
63 1581 caryophyllene oxide 0.2
64 1583 n.i. 0.2
65 1589 n.i. 0.2
66 1613 n.i. -
67 1615 n.i. -
68 1626 n.i. -
69 1630 gamma-eudesmol -
70 1641 epi-alpha-muurolol 1.0
71 1645 alpha-muurolol 0.4
72 1648 beta-eudesmol -
73 1653 alpha-cadinol 0.9
74 1682 epi-alpha-bisabolol 0.7
75 1684 alpha-bisabolol 0.3
76 1694 n.i. 3.1
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Measurement of fatty acid composition
Total lipids were extracted from different brain areas
and plasma using chloroform/methanol 2:1 (v/v) [40].
Aliquots were mildly saponified as previously described
[41] in order to obtain free fatty acids for high-perfor-
mance liquid chromatography (HPLC) analysis. Separa-
tion of fatty acids was carried out with an Agilent 1100
HPLC system (Agilent, Palo Alto, Calif., USA) equipped
with a diode array detector as previously reported [42].
Analysis of eCBs and congeners
N-arachidonoylethanolamide (AEA), 2-arachidonoyl-
monoacylglycerol (2-AG), palmitoylethanolamide (PEA)
and oleoylethanolamide (OEA) were extracted from tis-
sues and plasma, purified and analysed as previously
described [43].
One-way ANOVA and the Bonferroni test for post
h o ca n a l y s e sw e r ea p p l i e dt oe v aluate statistical differ-
ences among groups.
Western blot
Tissue homogenates were prepared in 2% sodium dode-
cyl sulphate (SDS). Protein concentrations were deter-
mined using the Lowry method of protein assay [44]
with bovine serum albumin as standard. Proteins for
each tissue homogenate (30 μg), diluted 1:1 in loading
buffer, were heated to 95°C for 10 min and separated by
SDS-polyacrilamide gel electrophoresis (SDS-PAGE)
using a 12.5% (w/v) polyacrylamide resolving gel. Inter-
nal mw standards (Kaleidoscope Prestained Standards,
Bio-Rad, Hercules, CA, USA) were run in parallel. Two
g e l sa tat i m ew e r er u nf o rC o o m a s s i es t a i n i n ga n d
immunoblotting, respectively. Proteins for immunoblot-
ting were electrophoretically transferred on a polyvinyli-
dene fluoride membrane (Bio-Rad) using the Mini Trans
Blot Cell (Bio-Rad). Blots were blocked by immersion in
20 mM Tris base and 137 mM sodium chloride (TBS)
containing 5% milk powder and 0.1% Tween 20 (TBS-
T), for 60 min at room temperature and incubated over-
night at 4°C with rabbit polyclonal antibody against
COX-2 (residues 570-598) (Cayman Chem., USA),
diluted 1:200 in TBS containing 5% milk powder and
0.02% sodium azide (NaN3) (Sigma-Aldrich, Steinheim,
Germany), was used as primary antiserum. After TBS-T
rinse, blots were incubated for 60 min, at room tem-
perature, with peroxidase-conjugated goat anti-rabbit
serum (Sigma Aldrich), diluted 1:10,000 in TBS/T.
Loading controls for equal loading of the wells were
obtained by stripping and immunostaining the mem-
branes as above, using a mouse monoclonal antibody
against the housekeeping protein glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) (Chemicon), diluted
1:1,000, as primary antiserum, and a peroxidase-conju-
gated goat anti-mouse serum (Chemicon), diluted
1:5,000, as secondary antiserum. In order to control for
non specific staining, blots were stripped and incubated
with the relevant secondary antiserum. After TBS-T
rinse, protein bands were visualized on a film (Kodak X-
Omat LS, Kodak, Rochester, NY) using the ECL method
(Amersham Corp.). Approximate molecular weight
(mw) of immunolabelled protein bands and relative
optical densities (ODs) were quantified using a GS-
800™ Calibrated Densitometer with Quantity One 1
analysis software (BIO-RAD Hercules, CA, USA) by
comparing the position of relevant bands on the autora-
diograms with those of the prestained standard mw or
with those of the GAPDH bands, respectively. The ratio
of the intensity of COX-2 bands to the intensity of
GAPDH bands was used to compare expression levels
of these proteins following E.O. administration. One-
way ANOVA and Fisher’s test for post hoc analyses
were applied to evaluate statistical differences among
groups.
Results
Fatty acid and eCB profiles in brain tissue
Analysis of the frontal cortex (Figure 1A) and the
remaining posterior cortex (Figure 1B) showed that, in
vehicle-treated rats, BCCAO/R affected fatty acid con-
centration by causing about 10% decrease of DHA in
12
13
14
15
16
sham + vehicle sham + E.O. BCCAO/R + vehicle BCCAO/R + E.O.
%
 
o
f
 
t
o
t
a
l
 
f
a
t
t
y
 
a
c
i
d
s
B
12
13
14
15
16
sham + vehicle sham + E.O. BCCAO/R + vehicle BCCAO/R + E.O.
%
 
o
f
 
t
o
t
a
l
 
f
a
t
t
y
 
a
c
i
d
s
a
a
b
a
A 
Figure 1 DHA concentration, expressed as mol% of total fatty
acids, in frontal (A) and posterior cortex (B) of rats submitted
to sham operation and to BCCAO/R, pre-treated either with the
vehicle alone or with the E.O.. Error bars depict standard
deviation. Different letters denote significant differences (p < 0.05).
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detected in the remaining posterior cortex (Figure 1B).
By contrast, no significant changes were evident in rats
pre-treated with E.O. and submitted to BCCAO/R as
compared with other groups (Figure 1). Analysis of
eCBs and congeners revealed no changes either after
BCCAO/R or E.O. pre-treatment (data not shown).
Fatty acid and eCB profiles in plasma
In order to verify whether there was a peripheral supply
of DHA, we also measured levels of DHA and its pre-
cursor EPA in plasma. In rats pre-treated with E.O.
whether or not submitted to BCCAO/R, an increase in
the DHA-to-EPA ratio (p < 0.05) was observed (Figure
2). Analysis of eCBs and congeners revealed that levels
of PEA and OEA increased significantly in rats pre-trea-
ted with E.O. and submitted to BCCAO/R (Figure 3)
compared to the vehicle-fed ones, whereas no change
was observed in levels of AEA and 2-AG.
Western blot
In the frontal cortex homogenate, the staining intensity
of the COX-2 protein band decreased significantly (p <
0.05) after pre-treatment with E.O. in the rats submitted
to BCCAO/R, as compared with the vehicle-fed rats
submitted to BCCAO/R (Figure 4). By contrast, no
changes were observed between vehicle-fed rats, both
after BCCAO/R or after sham operation.
Discussion
The present results show that BCCAO for 20 min fol-
lowed by reperfusion for 30 min is apt to induce a weak
but reproducible insult which resulted in a decrease of
DHA and a parallel increase of COX-2 expression in
frontal cortex, without any appreciable change in tissue
morphology. This model has proved to be useful to test
E.O. effects in the early phase of BCCAO/R, before
other factors may intervene triggering a range of physio-
logical responses to preserve structural lipid changes.
Previous studies reported failure of this model to
achieve a reproducible ischemic insult in the rodent
brain due to the presence of efficient collateral systems,
which allow for a cerebral blood flow compensation
within a few minutes [45,46]. Results obtained show
that this model triggers a cerebral insult sufficient to
cause a detectable, significant decrease in the tissue level
of DHA, the most abundant essential fatty acid of neu-
ronal membrane phospholipids [47]. DHA is particularly
susceptible to lipid peroxidation [48,49] and, for this
reason, potentially apt to contribute to hypoperfusion/
reperfusion-induced oxidative stress. However, several
lines of evidence have associated increased levels of
DHA to tissue protection in neuroinflammation [50]
suggesting that DHA does not increase susceptibility to
oxidative stress. Data in rodents and healthy humans
support this inferring, as dietary supplementation with
n-3 PUFAs does not affect lipid peroxidation [51,52].
DHA is an agonist of peroxisome proliferator-activated
receptor (PPAR) alpha [53]. Though mechanisms cer-
tainly need further investigation, it can be suggested
that PPARalpha, in turn, may act to attenuate the neu-
roinflammatory reaction either by increasing the rate of
peroxisomal beta-oxidation or by slowing/suppressing
nuclear factor-kappaB (NF-kB) activity and thereby
slowing the activity of phospholipases and COX-2 [54].
The present findings demonstrate that just a single
dose of E.O. is sufficient to influence tissue metabolism
in response to BCCAO/R challenge. The BCCAO/R-
induced decrease of DHA, most likely due to its break-
down during lipid peroxidation, was totally prevented by
the pre-treatment with E.O.. The observation that DHA/
EPA ratio raises after BCCAO/R following pre-treatment
with E.O. may lead to suggest that there is an increased
metabolism of n-3 which may supply damaged brain tis-
sue with newly produced DHA. On the other hand, the
increase of DHA/EPA ratio might be explained by an
augmented entry of EPA in the brain parenchyma to be
promptly metabolized to DHA [55,56]. Thus, in keeping
with the protecting role of DHA in neuroinflammation
[50], it is tempting to speculate that pre-treatment with
E.O. affects the outcome of the BCCAO/R-induced
events by modulating the tone of DHA precursors in
the brain. In this way, the sparing of DHA from lipid
peroxidation may contribute to minimize the extent of
the BCCAO/R-induced inflammatory reaction and to
help preserving the brain structure. The lower expres-
sion of COX-2 detected after BCCAO/R following pre-
treatment with E.O. compared to the treatment with the
vehicle alone further supports this hypothesis. In fact,
upregulation of COX-2 mRNA and protein, though not
always predictive of harmful effects [57-60], is induced
DHA/EPA
0,0
1,0
2,0
3,0
4,0
sham + vehicle sham + E.O. BCCAO/R + vehicle BCCAO/R + E.O.
a 
b
b
a 
Figure 2 DHA/EPA ratio in plasma of rats submitted to sham
operation and to BCCAO/R, pre-treated either with the vehicle
alone or with the E.O.. Error bars depict standard deviation.
Different letters denote significant differences (p < 0.05).
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[59,61-65]. Conversely, selective COX-2 inhibition ame-
liorates brain damage and prevents neuronal death after
ischemia [66].
An increase of eCB plasmatic levels has been shown in
several experimental models of ischemia [67]. In addi-
tion, in human stroke patients, an increase of PEA plas-
matic levels in early phases of ischemia has been
demonstrated to be significantly correlated with neuro-
logical disability [16]. In the present study PEA and
OEA are increased only in BCCAO/R rats pre-treated
with E.O.. Whether and how E.O. administration may
trigger an increase of PEA and OEA plasma levels
remains to be elucidated. As it has been suggested that
brain damage “spill over” effect may contribute to eCB
and congeners plasma levels [16], it would be further
interesting to establish if E.O. may cause or modulate
brain “spill over” in these conditions. On the other
hand, it has been widely demonstrated that PEA has
important pharmacological effects in a wide range of
experimental models of inflammation [68-70]. In parti-
cular, it is possible that PEA may exert neuroprotective
effects by preventing mast cell degranulation [71], acti-
vating PPARalpha [72] and dumping COX-2 expression
[68]. It could be speculated that the augmentation of
peripheral PEA might represent the key factor for
Figure 4 (A)Western blot analysis of COX-2 in the frontal cortex of rats submitted to sham operation and to BCCAO/R, pre-treated
either with the vehicle alone or with the E.O. (B) Relative levels of COX-2 expression with densitometric analysis of the gray levels expressed
as a percentage of the optical density (O.D.) ratio of the COX-2-positive bands to the GAPDH-positive ones. Error bars depict standard deviation.
Different letters denote significant differences (p < 0.05).
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Page 7 of 10enhancing PUFA metabolism via PPARalpha activation,
protecting brain from ischemia/reperfusion injury. Inter-
estingly, exogenous administration of PEA in an acute
stroke model is effective in reducing the infarct size
[73]. Moreover, in human stroke eCBs and congeners
become detectable in relation to the acute phase of
ischemic stroke [16] where they may play a role through
multiple potential mechanisms [16].
Conclusions
Previous studies tested the anti-oxidant, anti-microbial
and anti-inflammatory activities of the Pistacia lentiscus
L. gum or fixed oil [25,27,28,32,33]. However, to our
knowledge this is the first report on the effect of in vivo
administration of Pistacia lentiscus L. essential oil. There-
fore, identification of the E.O. constituent(s) that may
exert the beneficial effect in cerebral hypoperfusion/
reperfusion remains an issue worth further investigations.
A possible candidate is BCP, present in relatively high
concentration in the E.O., which has been shown to elicit
anti-inflammatory effects typical of non-steroidal agents
in rat models of inflammation [34-36] and to exert can-
nabimimetic effects in vivo [20,21]. In addition, potential
synergistic effects may be produced by other E.O. compo-
nents, such as alpha humulene, germacrene D, gamma-
cadinene, present in relatively high concentrations in
E.O., for which antioxidant and antinflammatory activities
have been also demonstrated [20,25,35].
Treatment with E.O. may prevent early neuroinflam-
matory events by protecting brain tissue DHA from oxi-
dative degradation, possibly allowing an attenuation of
signal transduction pathways which lead to increased
susceptibility to neuroinflammation. This effect may be
mediated by synergistic actions at peripheral and cere-
bral tissue level. Whether changes in brain and plasma
fatty acid metabolism are directly interrelated to avail-
ability and modifications of PEA and OEA concentration
in plasma is a suggestive issue worth to be further
investigated.
List of abbreviations
AEA: N-arachidonoylethanolamide; 2-AG: 2-arachidonoyl-monoacylglycerol;
BCCAO/R: bilateral common carotid artery occlusion followed by reperfusion;
BCP: beta-caryophyllene; COX-2: cyclooxygenase-2; DHA: docosahexaenoic
acid; eCB: endocannabinoid; E.O.: Pistacia lentiscus L. essential oil; EPA:
eicosapentaenoic acid; GAPDH: glyceraldehyde 3-phosphate dehydrogenase;
HPLC: high-performance liquid chromatography; HPUFA: highly
polyunsaturated fatty acid; NF-kB: nuclear factor-kappaB; OEA:
oleoylethanolamide; PPAR: peroxisome proliferator-activated receptor; PEA:
palmytoylethanolamide; PUFA: polyunsaturated fatty acid; SDS-PAGE: sodium
dodecyl sulfate-polyacrilamide gel electrophoresis; SFE: Supercritical Fluid
Extraction.
Acknowledgements
The authors gratefully acknowledge funding from the Regione Autonoma
della Sardegna “Green Chemistry” Cluster Project and the Fondazione Banco
di Sardegna.
Author details
1Department of Biomedical Sciences, University of Cagliari, Cittadella
Universitaria, Monserrato, Italy.
2Department of Chemical Sciences, University
of Cagliari, Cittadella Universitaria, Monserrato, Italy.
3Nutrisearch srl, Pula,
Italy.
Authors’ contributions
MQ and SB conceived the study, participated in its design and coordination,
draft and wrote the manuscript; MPS conceived and participated in the
design of the study, carried out the protein analysis and elaborated the data;
MB carried out the tissue sampling and performed the statistical analysis of
western blot data; GP and TM performed the surgery; LP helped in the
statistical analysis; MDF gave critical contribution to the manuscript; DF
performed the SFE; GC and EM, participated in the design of the study,
performed the eCB analysis and elaborated the data; LC and AP performed
the fatty acid analysis and elaborated the data. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 24 November 2011 Accepted: 12 January 2012
Published: 12 January 2012
References
1. Verhaeghe R, Naert J, Vermylen J: Bilateral carotid artery occlusion: clinical
presentation and outcome. Clin Neurol Neurosurg 1991, 93:123-126.
2. AbuRahma AF, Copeland SE: Bilateral internal carotid artery occlusion:
natural history and surgical alternatives. Cardiovasc Surg 1998, 6:579-583.
3. Martin RS, Edwards WH, Mulherin JL Jr, Edwards WH Jr: Surgical treatment
of common carotid artery occlusion. Am J Surg , 3 1993, 165:302-306.
4. Persoon S, Klijn CJ, Algra A, Kappelle LJ: Bilateral carotid artery occlusion
with transient or moderately disabling ischaemic stroke: clinical features
and long-term outcome. J Neurol 2009, 256:1728-1735.
5. Dirnagl U, Iadecola C, Moskowitz MA: Pathobiology of ischaemic stroke:
an integrated view. Trends Neurosci 1999, 22:391-397.
6. White BC, Sullivan JM, DeGracia DJ, O’Neil BJ, Neumar RW, Grossman LI,
Rafols JA, Krause GS: Brain ischemia and reperfusion: molecular
mechanisms of neuronal injury. J Neurol Sci 2000, 179(S1-2):1-33.
7. Traystman RJ, Kirsch JR, Koehler RC: Oxygen radical mechanisms of brain
injury following ischemia and reperfusion. J Appl Physiol 1991,
71:1185-1195.
8. Shi H, Liu KJ: Cerebral tissue oxygenation and oxidative brain injury
during ischemia and reperfusion. Frontiers in Bioscience 2007,
12:1318-1328.
9. Bazan NG: Synaptic lipid signaling: significance of polyunsaturated fatty
acids and platelet-activating factor. J Lipid Res 2003, 44:2221-2233.
10. Halliwell B: Oxidative stress and neurodegeneration: where are we now?
J Neurochem 2006, 97:1634-1658.
11. Adibhatla RM, Dempsey R, Hatcher JF: Integration of cytokine biology and
lipid metabolism in stroke. Frontiers in Bioscience 2008, 13:1250-1270.
12. Neuringer M, Connor WE, Lin DS, Barstad L, Luck S: Biochemical and
functional effects of prenatal and postnatal omega 3 fatty acid
deficiency on retina and brain in rhesus monkeys. Proc Natl Acad Sci USA
1986, 83:4021-4025.
13. Yoshida Y, Hayakawa M, Habuchi Y, Itoh N, Niki E: Evaluation of lipophilic
antioxidant efficacy in vivo by the biomarkers hydroxyoctadecadienoic
acid and isoprostane. Lipids 2007, 42:463-472.
14. Centonze D, Battistini L, Maccarrone M: The endocannabinoid system in
peripheral lymphocytes as a mirror of neuroinflammatory diseases. Curr
Pharm Des 2008, 14(23):2370-2342.
15. Banni S, Montisci R, Sanfilippo R, Finco G, Sanna D, Giordano E, Murru E,
Cordeddu L, Carta G, Banni D, Marchi A: Physiological response to lipid
peroxidation in ischemia and reperfusion during carotid
endarterectomy. Lipids Health Dis 2010, 9:41.
16. Naccarato M, Pizzuti D, Petrosino S, Simonetto M, Ferigo L, Grandi FC,
Pizzolato G, Di Marzo V: Possible anandamide and palmitoylethanolamide
involvement in human stroke. Lipids Health Dis 2010, 9:47.
17. Ungvari Z, Kaley G, de Cabo R, Sonntag WE, Csiszar A: Mechanisms of
vascular aging: new perspectives. J Gerontol A Biol Sci Med Sci 2010,
65:1028-1041.
Quartu et al. Lipids in Health and Disease 2012, 11:8
http://www.lipidworld.com/content/11/1/8
Page 8 of 1018. Curin Y, Ritz MF, Andriantsitohaina R: Cellular mechanisms of the
protective effect of polyphenols on the neurovascular unit in strokes.
Cardiovasc Hematol Agents Med Chem 2006, 4:277-288.
19. Sun AY, Wang Q, Simonyi A, Sun GY: Botanical phenolics and brain
health. Neuromolecular Med 2008, 10(4):259-274.
20. Gertsch J: Anti-inflammatory cannabinoids in diet: Towards a better
understanding of CB(2) receptor action? Commun Integr Biol 2008,
1:26-28.
21. Gertsch J, Leonti M, Raduner S, Racz I, Chen JZ, Xie XQ, Altmann KH,
Karsak M, Zimmer A: Beta-caryophyllene is a dietary cannabinoid. Proc
Natl Acad Sci USA 2008, 105:9099-9104.
22. Gertsch J: Botanical drugs, synergy, and network pharmacology: forth
and back to intelligent mixtures. Planta Med 2011, 77:1086-1098.
23. Sousa OV, Silvério MS, Del-Vechio-Vieira G, Matheus FC, Yamamoto CH,
Alves MS: Antinociceptive and anti-inflammatory effects of the essential
oil from Eremanthus erythropappus leaves. J Pharm Pharmacol 2008,
60(6):771-777.
24. Limem-Ben Amor I, Boubaker J, Ben Sgaier M, Skandrani I, Bhouri W,
Neffati A, Kilani S, Bouhlel I, Ghedira K, Chekir-Ghedira L: Phytochemistry
and biological activities of Phlomis species. J Ethnopharmacol 2009,
125:183-202.
25. Triantafyllou A, Bikineyeva A, Dikalova A, Nazarewicz R, Lerakis S, Dikalov S:
Anti-inflammatory activity of Chios mastic gum is associated with
inhibition of TNF-alpha induced oxidative stress. Nutr J 2011, 10:64.
26. Atzei AD: Le piante nella tradizione popolare della Sardegna Carlo Delfino
Editore Sassari: Italy; 2003, 221-222.
27. Magiatis P, Melliou E, Skaltsounis AL, Chinou IB, Mitaku S: Chemical
composition and antimicrobial activity of the essential oils of Pistacia
lentiscus var. chia. Planta Med 1999, 65(8):749-752.
28. Baratto MC, Tattini M, Galardi C, Pinelli P, Romani A, Visioli F, Pogni R:
Antioxidant activity of galloyl quinic derivatives isolated from Pistacia
lentiscus leaves. Free Radical Research 2003, 37:405-412.
29. Andrikopoulos NK, Kaliora AC, Assimopoulou AN, Papageorgiou VP:
Biological activity of some naturally occuring resins, gums and pigments
against in vitro LDL oxidation. Phytother Res 2003, 17:501-507.
30. Stocker P, Yousfi M, Djerridane O, Perrier J, Amziani R, El Boustani S, Moulin A:
Effect of flavonoids from various Mediterranean plants on enzymatic
activity of intestinal carboxylesterase. Biochimie 2004, 86:919-925.
31. Ljubuncic P, Azaizeh H, Portnaya I, Coganc U, Said O: Antioxidant activity
and cytotoxicity of eight plants used in traditional Arab medicine in
Israel. Journal of Ethnopharmacology 2005, 99:43-47.
32. Barra A, Coroneo V, Dessì S, Cabras P, Angioni A: Characterization of the
volatile constituents in the essential oil of Pistacia lentiscus L. from
different origins and its antifungal and antioxidant activity. J Agric Food
Chem 2007, 55:7093-7098.
33. Gardeli C, Vassiliki P, Athanasios M, Kibouris T, Komaitis M: Essentail oil
composition of Pistacia lentiscus L and Myrtus communis L., evaluation of
antioxidant capacity of methanolic extracts. Food Chemistry 2008,
107:1120-1130.
34. Tambe Y, Tsujiuchi H, Honda G, Ikeshiro Y, Tanaka S: Gastric cytoprotection
of the non-steroidal anti-inflammatory sesquiterpene, beta-
caryophyllene. Planta Med 1996, 62:469-470.
35. Fernandes ES, Passos GF, Medeiros R, da Cunha FM, Ferreira J, Campos MM,
Pianowski LF, Calixto JB: Anti-inflammatory effects of compounds alpha-
humulene and (-)-trans-caryophyllene isolated from the essential oil of
Cordia verbenacea. Eur J Pharmacol 2007, 569:228-236.
36. Passos GF, Fernandes ES, da Cunha FM, Ferreira J, Pianowski LF,
Campos MM, Calixto JB: Anti-inflammatory and anti-allergic properties of
the essential oil and active compounds from Cordia verbenacea. J
Ethnopharmacol 2007, 110:323-333.
37. Marongiu B, Piras A, Porcedda S, Scorciapino A: Chemical composition of
the essential oil and supercritical CO2 extract of Commiphora myrrha
(Nees) Engl. and of Acorus calamus L. J Agric Food Chem 2005, 53:7939-43.
38. Adams RP: Identification of Essential Oil Component by Gas
chromatography/ Quadrupole Mass spectroscopy. Allured publishing
corporation Illinois, USA; 2004.
39. Joulain D, König WA: The atlas of spectral data of sesquiterpene
hydrocarbons. E.B.-Verlag, Hamburg; 1998.
40. Folch J, Lees M, Sloane Stanley GH: A simple method for the isolation and
purification of total lipides from animal tissues. J Biol Chem 1957,
226:497-509.
41. Banni S, Carta G, Contini MS, Angioni E, Deiana M, Dessi MA, Melis MP,
Corongiu FP: Characterization of conjugated diene fatty acids in milk,
dairy products, and lamb tissues. J Nutr Biochem 1996, 7:150-155.
42. Melis MP, Angioni E, Carta G, Murru E, Scanu P, Spada S, Banni S:
Characterization of conjugated linoleic acid and its metabolites by
RPHPLC with diode array detector. Eur J Lipid Sci Technol 2001,
103:617-621.
43. Di Marzo V, Goparaju SK, Wang L, Liu J, Bàtkai S, Jàrai Z, Fezza F, Miura GI,
Palmiter RD, Sugiura T, Kunos G: Leptin-regulated endocannabinoids are
involved in maintaining food intake. Nature 2001, 410:822-825.
44. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurements with
the Folin phenol reagent. J Biol Chem 1951, 193:265-275.
45. De Ley G, Nshimyumuremyi JB, Leusen I: Hemispheric blood flow in the
rat after unilateral common carotid occlusion: evolution with time. Stroke
1985, 16(1):69-73.
46. Coyle P, Panzenbeck MJ: Collateral development after carotid artery
occlusion in Fischer 344 rats. Stroke 1990, 21:316-321.
47. Garcia MC, Ward G, Ma YC, Salem N, Kim HV: Effect of docosahexaenoic
acid on the synthesis of phosphatidylserine in rat brain in microsomes
and c6 glioma cells. J Neurochem 1998, 70:24-30.
48. Ahmad A, Moriguchi T, Salem N: Decrease in neuron size in
docosahexaenoic acid-deficient brain. Pediatr Neurol 2002, 26:210-218.
49. Niemoller DT, Bazan NG: Docosahexaenoic acid neurolipidomics.
Prostaglandins Other Lipid Mediat 2010, 91:85-89.
50. Strokin M, Sergeeva M, Reiser G: Role of Ca
2+-independent phospholipase
A2 and n-3 polyunsaturated fatty acid docosahexaenoic acid in
prostanoid production in brain: perspectives for protection in
neuroinflammation. Int J Devl Neurosci 2004, 22(7):551-557.
51. Ando K, Nagata K, Yoshida R, Kikugawa K, Suzuki M: Effect of n-3
polyunsaturated fatty acid supplementation on lipid peroxidation of rat
organs. Lipids 2000, 35:401-407.
52. Nälsén C, Vessby B, Berglund L, Uusitupa M, Hermansen K, Riccardi G,
Rivellese A, Storlien L, Erkkilä A, Ylä-Herttuala S, Tapsell L, Basu S: Dietary (n-
3) fatty acids reduce plasma F2-isoprostanes but not prostaglandin
F2alpha in healthy humans. J Nutr 2006, 136:1222-1228.
53. Na HK, Surh YI: peroxisome proliferator-activated receptor gamma
(PPARγ) ligands as bifunctional regulators of cell proliferation. Biochem
Pharmacol 2003, 66:1381-1391.
54. Pyper SR, Viswakarma N, Yu S, Reddy JK: PPARalpha: energy combustion,
hypolipidemia, inflammation and cancer. Nucl Recept Signal 2010, 8:
e002.
55. Kaduce TL, Chen Y, Hell JW, Spector AA: Docosahexaenoic acid synthesis
from n-3 fatty acid precursors in rat hippocampal neurons. J Neurochem
2008, 105:1525-1535.
56. Chen CT, Liu Z, Bazinet RP: Rapid de-esterification and loss of
eicosapentaenoic acid from rat brain phospholipids: an
intracerebroventricular study. J Neurochem 2011, 116:363-373.
57. Miettinen S, Fusco FR, Yrjänheikki J, Keinänen R, Hirvonen T, Roivainen R,
Närhi M, Hökfelt T: Koistinaho Spreading depression and focal brain
ischemia induce cyclooxygenase-2 in cortical neurons through N-
methyl-D-aspartic acid-receptors and phospholipase A2. Proc Natl Acad
Sci USA 1997, 94:6500-6505.
58. Walton M, Sirimanne E, Williams C, Gluckman PD, Keelan J, Mitchell MD,
Dragunow M: Prostaglandin H synthase-2 and cytosolic phospholipase
A2 in the hypoxic-ischemic brain: role in neuronal death or survival?
Brain Res Mol Brain Res 1997, 50:165-170.
59. Choi JS, Kim HY, Chun MH, Chung JW, Lee MY: Differential regulation of
cyclooxygenase-2 in the rat hippocampus after cerebral ischemia and
ischemic tolerance. Neurosci Lett 2006, 393:231-236.
60. Park MK, Kang YJ, Lee HS, Kim HJ, Seo HG, Lee JH, Chang KC: The
obligatory role of COX-2 expression for induction of HO-1 in ischemic
preconditioned rat brain. Biochem Biophys Res Commun 2008,
377:1191-1194.
61. Nakayama M, Uchimura K, Zhu RL, Nagayama T, Rose ME, Stetler RA,
Isakson PC, Chen J, Graham SH: Cyclooxygenase-2 inhibition prevents
delayed death of CA1 hippocampal neurons following global ischemia.
Proc Natl Acad Sci USA 1998, 95(18):10954-10959.
62. Matsuoka Y, Okazaki M, Zhao H, Asai S, Ishikawa K, Kitamura Y:
Phosphorylation of c-Jun and its localization with heme oxygenase-1
and cyclooxygenase-2 in CA1 pyramidal neurons after transient
forebrain ischemia. J Cereb Blood Flow Metab 1999, 19:1247-1255.
Quartu et al. Lipids in Health and Disease 2012, 11:8
http://www.lipidworld.com/content/11/1/8
Page 9 of 1063. Koistinaho J, Koponen S, Chan PH: Expression of cyclooxygenase-2 mRNA
after global ischemia is regulated by AMPA receptors and
glucocorticoids. Stroke 1999, 30:1900-1905, discussion 1905-1906.
64. Collino M, Aragno M, Mastrocola R, Benetti E, Gallicchio M, Dianzani C,
Danni O, Thiemermann C, Fantozzi R: Oxidative stress and inflammatory
response evoked by transient cerebral ischemia/reperfusion: effects of
the PPAR-alpha agonist WY14643. Free Radic Biol Med 2006, 41:579-589.
65. Yamashita A, Kunimatsu T, Yamamoto T, Yoshida K: Hypothermic, but not
normothermic, ischemia causes a drastic increase in cyclooxygenase-2
immunoreactive granule cells in rat dentate gyrus after 4 hours of
ischemic reperfusion. Arch Histol Cytol 2007, 70:197-205.
66. Candelario-Jalil E, Fiebich BL: Cyclooxygenase inhibition in ischemic brain
injury. Curr Pharm Des 2008, 14:1401-1418.
67. Pellegrini-Giampietro DE, Mannaioni G, Bagetta G: Post-ischemic brain
damage: the endocannabinoid system in the mechanisms of neuronal
death. FEBS J 2009, 276:2-12.
68. Costa B, Conti S, Giagnoni G, Colleoni M: Therapeutic effect of the
endogenous fatty acid amide, palmitoylethanolamide, in rat acute
inflammation: inhibition of nitric oxide and cyclo-oxygenase systems. Br
J Pharmacol 2002, 137:413-420.
69. De Filippis D, D’Amico A, Cipriano M, Petrosino S, Orlando P, Di Marzo V,
Iuvone T: Levels of endocannabinoids and palmitoylethanolamide and
their pharmacological manipulation in chronic granulomatous
inflammation in rats. Pharmacol Res 2010, 61:321-328.
70. Endocannabinoid Research Group, De Filippis D, D’Amico A, Cipriano M,
Petrosino S, Orlando P, Di Marzo V, Iuvone T: Levels of endocannabinoids
and palmitoylethanolamide and their pharmacological manipulation in
chronic granulomatous inflammation in rats. Pharmacol Res 2010,
61:321-328.
71. Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A: Mast cells
express a peripheral cannabinoid receptor with differential sensitivity to
anandamide and palmitoylethanolamide. Proc Natl Acad Sci USA 1995,
92:3376-3380.
72. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, Piomelli D:
The nuclear receptor peroxisome proliferator-activated receptor-alpha
mediates the anti-inflammatory actions of palmitoylethanolamide. Mol
Pharmacol 2005, 67:15-19.
73. Schomacher M, Müller HD, Sommer C, Schwab S, Schäbitz WR:
Endocannabinoids mediate neuroprotection after transient focal cerebral
ischemia. Brain Res 2008, 1240:213-220.
doi:10.1186/1476-511X-11-8
Cite this article as: Quartu et al.: Effect of acute administration of
Pistacia lentiscus L. essential oil on rat cerebral cortex following
transient bilateral common carotid artery occlusion. Lipids in Health and
Disease 2012 11:8.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Quartu et al. Lipids in Health and Disease 2012, 11:8
http://www.lipidworld.com/content/11/1/8
Page 10 of 10